Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | SELE | P16581 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8887331 | 0.86 | KDM4C (0.41) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL29176754 | 0.82 | KDM4E (0.42) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL3445830 | 0.81 | ABCB1 (0.42) | KDM4CMEN1KMT2ANPC1RAB9A | |
| SCHEMBL12634793 | 0.81 | KDM4C (0.47) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL3446035 | 0.81 | HPGD (0.42) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL1345450 | 0.81 | KDM4C (0.49) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL18796462 | 0.80 | KDM4C (0.38) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL12375131 | 0.80 | GABRA1 (0.46) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL29234119 | 0.79 | MEN1 (0.46) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL12634794 | 0.79 | KDM4C (0.47) | KDM4CMEN1KMT2AL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016285-A1 | Boron-Containing Small Molecules | ANACOR PHARMACEUTICALS, LLC | 2018-01-18 | — | — | US | disclosed |
| EP-2164331-B1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS INC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-9796735-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20150133402-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, LLC | 2015-05-14 | — | — | US | disclosed |
| US-8895534-B2 | Boron containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20100292504-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-7816344-B2 | oxaboroles such as 3-[[(3S)-3-(aminomethyl)-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]propan-1-ol, useful for treating bacterial infections; microbiocides; antibiotics | ANACOR PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| EP-2164331-A1 | BORON-CONTAINING SMALL MOLECULES | Anacor Pharmaceuticals, Inc. (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20090227541-A1 | oxaboroles such as 3-[[(3S)-3-(aminomethyl)-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]propan-1-ol, useful for treating bacterial infections; microbiocides; antibiotics | ANACOR PHARMACEUTICALS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| WO-2008157726-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292504-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BLVRB, BCL6 | KDM4C 3800/4885MEN1 204/4885KMT2A 3169/4885 |
| US-20150133402-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BLVRB, BCL6 | KDM4C 3800/4885MEN1 204/4885KMT2A 3169/4885 |
| US-20090227541-A1 | oxaboroles such as 3-[[(3S)-3-(aminomethyl)-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]propan-1-ol, useful for treating bacterial infections; microbiocides; antibiotics | OXA1L, TLR1, OXER1 | KDM4C 3152/4885MEN1 3905/4885KMT2A 4542/4885 |
| US-20180016285-A1 | Boron-Containing Small Molecules | BCL6B, BLVRB, BCL6 | KDM4C 3800/4885MEN1 204/4885KMT2A 3169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.